バイオメア・フュージョン
Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.17 | $0 | -$12M |
| 2025 Q4 | 0.06 | $0 | -$13M |
| 2025 Q3 | -0.27 | $0 | -$12M |
| 2025 Q2 | -0.51 | $0 | -$19M |
| 2025 Q1 | -0.80 | $0 | -$26M |
| 2024 Q4 | -0.81 | $0 | -$30M |
| 2024 Q3 |
| -0.91 |
| $0 |
| -$25M |
| 2024 Q2 | -1.03 | $0 | -$33M |